Form 4: Lyell Immunopharma CEO Acquires Shares, Sells for Tax

Lyell Immunopharma's President and CEO, Lynn Seely, acquired 40,000 shares of common stock due to performance criteria achievement and sold 7,257 shares to cover tax withholding obligations.

Summary

• Lynn Seely, President and CEO of Lyell Immunopharma, Inc., acquired 40,000 shares of common stock.
• 20,000 of these shares were issued on August 20, 2025, following the achievement of specific performance criteria certified by the compensation committee.
• An additional 20,000 shares are scheduled to be issued on August 20, 2026, contingent on continued service.
• Seely subsequently sold 7,257 shares of common stock on August 21, 2025, at a weighted average price of $10.544 per share.
• This sale was an automatic transaction to cover tax withholding obligations arising from the settlement of vested restricted stock units.
• Following these transactions, Lynn Seely beneficially owns 67,571 shares of Lyell Immunopharma common stock.

Sentiment

Score: 7

Explanation: The filing indicates positive performance achievement leading to share issuance, which is a good sign. The subsequent sale is for tax purposes, a routine event, and not indicative of negative sentiment from management.

Positives

• Acquisition of 40,000 shares of common stock by the President and CEO, Lynn Seely, indicating increased direct ownership.
• 20,000 shares were issued due to the achievement of specific performance criteria, certified by the compensation committee, reflecting successful execution against company goals.

Negatives

• Sale of 7,257 shares by the CEO, although for tax withholding, reduces direct ownership.

Future Outlook

An additional 20,000 shares of common stock are scheduled to be issued to Lynn Seely on August 20, 2026, contingent upon her continued service to the company.

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased direct ownership by the CEO (net of tax sales) could be seen as a positive signal of alignment with shareholder interests. Performance-based vesting indicates management is meeting goals.
• Employees: The vesting of performance-based restricted stock units can serve as an example of successful incentive compensation for other employees.

Next Steps

• Issuance of an additional 20,000 shares to Lynn Seely on August 20, 2026, subject to her continued service.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions, specifically the vesting of performance-based restricted stock units and a subsequent sale to cover tax obligations. While the performance-based vesting is a positive indicator of management achieving goals, the overall transaction volume and nature are not significant enough to warrant a strong buy or sell recommendation. It primarily reflects standard executive compensation practices and does not provide new fundamental information to alter an existing investment thesis. Therefore, a 'hold' recommendation is appropriate as it maintains current positions without suggesting new action based solely on this filing.

Keywords

Lyell Immunopharma, LYEL, Lynn Seely, Insider Trading, Form 4, Stock Grant, Restricted Stock Units, Tax Withholding, CEO Stock, Biotechnology